Assembly Biosciences, Inc. (ASMB) NASDAQ
24.49
-2.43(-9.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
24.49
-2.43(-9.03%)
Currency In USD
Address
331 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
833 509 4583
Website
Sector
Healthcare
Industry
Biotechnology
Employees
73
First IPO Date
December 17, 2010
| Name | Title | Pay | Year Born |
| Jason A. Okazaki | Chief Executive Officer, President & Director | 1.25M | 1976 |
| Thomas E. Rollins | Executive Officer | 472,550 | 1956 |
| Nicole S. White | Chief Manufacturing Officer | 655,840 | 1980 |
| Anuj Gaggar | Chief Medical Officer | 820,673 | 1978 |
| William E. Delaney | Chief Scientific Officer | 829,367 | 1972 |
| Jeanette Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | 0 | 1987 |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | 0 | N/A |
| Jennifer A. Troia MHROD SHRM-SCP SPHR | Chief Human Resources Officer | 0 | N/A |
| Amy Figueroa | Investor Relations Consultant | 0 | N/A |
| Katie Kitrinos | Senior Vice President of Preclinical Research & Development | 0 | N/A |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.